Conclusions
GLS did not predict long-term outcome in patients presenting to the ED with chest pain and suspected ACS with neither a diagnostic ECG or elevated cardiac enzymes. These data support our findings in the original 2DSPER multicenter study, and together with the SUCCOUR study, emphasize the need for large prospective trials to evaluate the clinical utility of GLS. We conclude that 2DLS is not a useful tool for the diagnosis of ACS and for predicting outcome in low to intermediate risk patients presenting to the ED with chest pain and suspected ACS.
Conflict of interest: NLC, DSB, SS, MJ, ML and AS report non-financial support from GE Healthcare, Haifa, Israel, during the conduct of the study.